Innovative Bispecific Nanobody Targeting FCGR3A and ROR1 for Next-Generation Autoimmune Disease Therapy

VHH-P221 is a bispecific, humanized nanobody designed to simultaneously target Fc gamma receptor IIIa (FCGR3A) and receptor tyrosine kinase-like orphan receptor 1 (ROR1). The construct is currently in the Biological Testing phase, demonstrating strong potential as a novel therapeutic option for autoimmune disease. By directing action specifically at both FCGR3A and ROR1, VHH-P221 is engineered to modulate pathological immune responses at multiple regulatory nodes, paving the way for a more precise and effective intervention in autoimmune processes. This program leverages the advantages of nanobody technology to address unmet needs in the autoimmune disease treatment landscape.

Licensing Opportunity

VHH-P221 is available for out-licensing and collaborative development. Partners interested in leveraging this innovative bispecific nanobody platform for autoimmune disease therapeutics are welcome to discuss cooperation opportunities.

Development Phase

Modality

VHH-P221 is a bispecific antibody fusion construct comprising an anti-human CD16A single-domain antibody fused to a human IgG1 Fc, and further linked via a (G4S)3 flexible peptide tether to an anti-human ROR1 single-chain variable fragment. Produced in HEK293 cells, this structure combines the small molecular size and robust stability of single-domain antibodies with the effector functionality of the IgG1 Fc. The bispecific format allows for dual target engagement, offering enhanced tissue penetration and favorable pharmacokinetics. These properties are particularly advantageous in treating autoimmune disease, as they may enable VHH-P221 to efficiently access inflamed tissues and orchestrate targeted immune modulation with high specificity and potential improved safety.

Target

FCGR3A and ROR1 are both critical molecular targets in immune modulation. FCGR3A is an immune cell surface receptor fundamentally involved in antibody-dependent cellular responses and found predominantly on natural killer cells and certain myeloid cells. ROR1 is a transmembrane receptor with pivotal roles in signal transduction, and although its expression is limited in normal adult tissues, it is often upregulated under pathological conditions, including some autoimmune diseases. The dual targeting of FCGR3A and ROR1 by VHH-P221 addresses both the effector and regulatory components of immune dysregulation. Targeting FCGR3A can help attenuate aberrant immune activation, while engagement of ROR1 may modulate intrinsic autoimmune signaling pathways. This bispecific approach provides strategic depth for therapeutic development, positioning VHH-P221 as a highly attractive asset in the autoimmune disease pipeline.

Mechanism of Action

VHH-P221 acts as a signal transduction modulator by binding both FCGR3A and ROR1, simultaneously interfering with key checkpoints that drive pathological immune responses in autoimmune disease. The anti-FCGR3A domain binds to immune cell receptors implicated in antibody-driven effector functions, potentially reducing excessive immune cell activation. Concurrently, the anti-ROR1 fragment targets aberrant receptor signaling in disease-relevant cells. This dual engagement is designed to recalibrate immune signaling at multiple levels, aiming to restore physiological immune balance. The modular design of nanobody-based fusion proteins such as VHH-P221 further allows for the development of advanced formats, including bispecifics and antibody-drug conjugates, enhancing versatility for future therapeutic expansion.

Autoimmune Disease

Autoimmune diseases encompass a broad category of chronic disorders characterized by an inappropriate immune response against self-tissues, leading to inflammation and tissue damage. They affect millions of individuals worldwide and include conditions such as rheumatoid arthritis, systemic lupus erythematosus, and multiple sclerosis. Current mainstay treatments often involve broad-spectrum immunosuppressants, corticosteroids, and in some cases, targeted biologics. Despite these options, a substantial proportion of patients experience incomplete responses, adverse effects, or progressive disease, underscoring significant unmet clinical needs. Moreover, long-term immunosuppression may lead to increased infection risk and other complications. VHH-P221’s dual specificity for FCGR3A and ROR1 offers a novel, targeted approach that may provide selective immune regulation with potentially improved safety and efficacy. As such, it has the potential to address core pathogenic mechanisms in autoimmune disease and improve outcomes for patients historically underserved by conventional therapies.